- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05032833
Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects
October 10, 2022 updated by: Beckley Psytech Limited
A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects
The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom
- King's College London
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
23 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
* Medically healthy based on medical records and study specific assessments
Exclusion Criteria:
* Presence or history of severe adverse reaction to any drug or drug excipient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo arm
|
A single dose of placebo will be administered intranasally
|
Experimental: 5-MeO-DMT arm
|
A single dose of 5-MeO-DMT will be administered intranasally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of subjects with treatment emergent AEs (TEAES)
Time Frame: From screening through to the follow up visit, up to 65 days
|
From screening through to the follow up visit, up to 65 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Peak plasma concentration (Cmax)
Time Frame: Day 1 (dosing day) and Day 2
|
Day 1 (dosing day) and Day 2
|
Time to reach Cmax (tmax)
Time Frame: Day 1 (dosing day) and Day 2
|
Day 1 (dosing day) and Day 2
|
Area under the plasma concentration- time curve
Time Frame: Day 1 (dosing day) and Day 2
|
Day 1 (dosing day) and Day 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 22, 2021
Primary Completion (Actual)
July 7, 2022
Study Completion (Actual)
July 7, 2022
Study Registration Dates
First Submitted
August 24, 2021
First Submitted That Met QC Criteria
August 27, 2021
First Posted (Actual)
September 2, 2021
Study Record Updates
Last Update Posted (Actual)
October 12, 2022
Last Update Submitted That Met QC Criteria
October 10, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- BPL-5MEO-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Due to the UK GDPR, individual participant data will not be shared publicly.
Group data will be presented in publication after study completion
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacokinetics in Healthy Adults
-
Beckley Psytech LimitedCompletedPharmacokinetics in Healthy AdultsUnited Kingdom
-
scPharmaceuticals, Inc.CompletedPharmacokinetics in Healthy Adults
-
Daiichi Sankyo, Inc.CompletedPharmacokinetics in Healthy VolunteersUnited States
-
Baystate Medical CenterCompleted
-
University of ZurichCompletedMotivation in Healthy Older AdultsSwitzerland
-
Stony Brook UniversityMartinos Center for Biomedical ImagingCompleted
-
SyralBeghin-MeijiCompleted
-
Daiichi Sankyo, Inc.CompletedDrug Pharmacokinetics in Healthy VolunteersUnited States
-
Colorado State UniversityCompletedMild Gastrointestinal Symptoms in Healthy AdultsUnited States
-
Mount St. Mary's College, Los Angeles, CAUnknownPhysiology of Manipulation / Mobilization in Healthy AdultsUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States